The incidence of acute myeloid leukemia (AML) increases with age, but results of intensive chemotherapy in elderly patients are disappointing. Non-pegylated Iiposomal formulations of doxorubicin (Myocet"') have been developed with the aim of reducing systemic and cardiac toxicity especially in the elderly. We evaluated the efficacy and toxicity profiles of fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) regimen given in association with MyocefMin 35 patients with AML, median age 69 years (range 61-83 years). Nineteen (54.3%) had newly-diagnosed AML, twelve (34.3%) patients had secondary AML (ten with Myelodisplastic Syndrome, two with Primary Myelofibrosis) and 4 (11.4%) patients had had a late relapse (> 12 months) of AML. Complete remission (CR) and partial remission (PR) were obtained in twenty-two (63%) and 3 (8.5%) patients, respectively. Seven (20%) patients showed a resistant disease. There were 3 early deaths (8.5%). Six patients (17%) experienced severe cardiovascular toxicity. The median overall survival (OS) was 12 months (range 1-52 months) with a median disease-free survival (DFS) of20 months (range 1-48 months). One-year and two-year DFS were 78.9% and 26.7%, respectively. This study demonstrates that in elderly patients with AML, FLAG-Myocef M combination shows promising efficacy response with acceptable toxicity, enabling most patients to receive further treatments, including transplantation procedures.
The incidence of acute myeloid leukemia (AML) increases with age: more than 50% of patients with AML are 60 years age or older. Elderly patients have a poor outcome, with complete remission (CR) rates of about 50% and median survival of only 8-12 months in those in whom intensive chemotherapy is applied for remission induction (1-4). Older age is a major determinant of outcome in these groups of patients, but also other negative prognostic factors have to be taken into account: poor performance status, concomitant diseases as well as antecedent hematologic disorders (such as myelodysplastic syndromes or chronic myeloproliferative neoplasms), history of prior chemotherapy and unfavourable cytogenetics (5) .
There is general agreement that some sort ofpostremission treatment should be used after reaching CR. However, aggressive, post-remission consolidation chemotherapy does not appear to improve survival in elderly patients, who are at increased risk of chemotherapy-related mortality. Consolidation of AML in first complete CR with high-dose cytarabine is not usually feasible and is associated with more toxic deaths and relapses in patients >60 years (6) (7) (8) . Recent studies have reported the feasibility of autologous peripheral blood stem cell transplantation (ASCT) in elderly AML patients, including patients aged more than 70 years (9) (10) (11) (12) (13) . To date, there is no accepted post-remission treatment in elderly patients with established efficacy.
The combination of fludarabine, cytarabine, and granulocyte colony-stimulating factor (G-CSF) (FLAG) +/anthracyclines has been reported to be effective and well tolerated in newly diagnosed patients with AML as well as in patients with poor risk AML (14) (15) (16) (17) .
Non-pegylated liposomal formulations of doxorubicin (Myocet") have been developed with the aim of improving the therapeutic index of doxorubicin: these formulations show an antileukemic activity equal or superior to standard doxorubicin, with reduced systemic and cardiac toxicity (18) . This profile could allow a more extensive chemotherapy approach in elderly patients with AML who often have cardiac diseases and for whom age represents a risk factor for cardiotoxicity (19) (20) .
The primary objective of the current study is to evaluate the efficacy and safety of a combination regimen of FLAG-Myocef M in elderly patients with AML. The secondary objective is the evaluation of the effect of post-remission therapy in order to achieve a longer survival in responsive patients.
MATERIALS AND METHODS
Between September 2006 and December 20 I0, patients over 60 years of age with AMl were treated with Fl.Afi-Myocet" regimen. The protocol for the study was approved by the Ethics Committee of our Hospital and all patients gave their written informed consent. Other inclusion criteria were: serum bilirubin level <2 mg/dl., creatinine <2 rng/dl., no documented active infections or history of recent myocardial infarction, severe cardiac dysfunction or life-threatening arrhythmias, a left ventricular ejection fraction (lVEF) >50% at the echocardiography, and a performance status (PS) assessed according to the WHO criteria between 0 and 3.
Diagnosis was made according to the French-American-British (FAB) Group criteria (21) . As shown in Table I, 19 patients had a newly-diagnosed non-M3 AMl with a minimum of 30% blast infiltrate in the bone marrow (BM), 12 a secondary disease (10 evolving from MDS and 2 from Primary Myelofibrosis) and 4 (two after ASCT) had had a late (> 12 months) relapse of AML. Detection of FlT3 mutation was performed by RT-PCR analysis on BM samples at diagnosis of 19 patients with newly-diagnosed AML. During the period of the study, the ratio between AMl patients over 60 years of age observed in our Institution and patients accrued into the trial were registered.
Patients were treated with FlAG-Myocet'": f1udarabine 30 mg/mvday was administered as a I hour intravenous infusion for 5 consecutive days. Three hours after this administration, 2 g/rrr' (I g/rn? if age>70 years) cytarabine was given by intravenous infusion over 4 hours; Myocet" 30 mg/m-was infused. once on day 3. If the patient's white blood cell count (WBC) was <2000/lll, recombinant human G-CSF (filgrastim or lenograstim) was administered at a dose of 5 ug/kg from day 0 (before starting chemotherapy) until neutrophils recovery. Patients who achieved either CR or partial response (PR) underwent a second similar FlAG-MyoCet'M cycle.
CR for this study was defined as a morphologically normal marrow with <5% blasts, together with normal peripheral and differential counts, including neutrophils and platelet (PTl) count> I,OOO/Ill and> 100,000/lll, respectively. PR was defined as normal peripheral and differential blood counts, neutrophils 2: I,OOO/Ill and platelet> IOO,OOO/Ill and less than 5% blasts in peripheral blood and less than 20% in the bone marrow aspirate. Toxicity was evaluated using CTC criteria 4.03.
The patients who achieved a CR after Fl.Atf-Myocet" treatment received an individualized program, including hematopoietic stem cell transplantation and/or monthly Gemtuzumab Ozogamicin (GO) maintenance or nothing, according to age and PS.
Overall survival (OS) was defined as the time from admission to either death or last follow-up, at which time a patient was censored. DFS was defined as the time from CR achievement to either relapse or death from any cause or to last follow-up, corresponding to the moment in which the patient is censored.
Statistical analysis
All analyses were performed using the Statistical Package for Social Science (SPSS version 13, Inc, Chicago, III, USA). Continuous variables were expressed as median values, ranges. and percentages. Survival analyses for OS and DFS were performed according to 
RESULTS
Between September 2006 and December 2010, 35 patients (16 women and 19 men) median age 69 years (range 61-83 years) with AML were treated with FLAG-MyoCet'M regimen. Twenty-two patients (63%) were aged 61-70 years, ten (28.6%) were aged 71-75 years and 3 (8.5%) patients were over 75 years of age at diagnosis. According to age, the rate of inclusion in the study was 65% for patients aged 61-70 years and 40% for those >70 years. PS was 0, I, 2, 3 in 6, II, 13, and 5 patients, respectively. Twenty-two patients had > I co-morbidity (14 cardiovascular). The median follow-up of patients was 12 months (range 0 -52 months). Median WBC count was 16,990 /IlL (range 500-579,000). FLT3 mutation was detected in 5/19 (26.3%) patients with newly-diagnosed AML.
Twenty-two (63%) patients achieved CR (19 after a single course of treatment) and 3 patients achieved PR (8.5%) for an overall response rate (ORR) of 71.5%. In patients with newly-diagnosed AML, secondary AML and relapsed AML, the CR rates were 68%, 50% and 75%, respectively. Seven patients (20%) experienced resistant disease. There were 3 early deaths (8.5%) (Table II) . Of the patients in CR after FLAG-Myocef M induction treatment, one died at day +30 from adult respiratory distress syndrome and three died before the second course (I due to gastrointestinal toxicity and 2 due to cardiac arrest 20-30 days after discharge apparently unrelated to previous treatment). Overall, 30 and 60 day mortality rates for all causes were 11.4% (4 patients) and 20% (7 patients), respectively. Of the patients who achieved a CR, eight patients aged under 70 years received hematopoietic stem cell transplantation: allogeneic HSCT (I patient) and ASCT with peripheral blood stem cell collected after the second FLAG-MyoCet'M course (7 patients). After ASCT, 4 patients with normal peripheral and differential counts, including neutrophils and PLT counts of> 1000/IlL and> 100,000/IlL, respectively, received maintenance treatment with monthly GO (3 mg/m2) for 4 months. At a median follow-up of 17 months (range 8-48), relapse occurred in 5 out of 7 patients at +8, + 14, + 17, + 18 months and + 40 months after ASCT, respectively. One patient relapsed 24 months after allogeneic HSCT. Eight patients in CR were considered not eligible for transplantation and received monthly GO maintenance (3 mg/m-) for 6 months for a median of 4 cycles (range 1-6). At a median follow-up of 14 months (range 8-52) five were alive (three in continuous CR). Three patients did not receive any further treatment.
In December 2010, 8/35 patients (34.4% of the total population) were alive and six were in continuous CR. Median OS and DFS were 12 (range 1-52) months and 20 (range 1-48) months, respectively. One-year and 2-year DFS were 78.9 % *There were a cardiac arrest and multi-organfailure leading to two early deaths. Twopatients died in CR due to cardiac arrest at 30 days after discharge: all of them had a previous history of cardiac disease. One ventricular arrhythmia following grade 3 hypoka/iemia and one grade 3 atrial fibrillation were observed." I 7 bacterial and 2 fungal. and 26.7 %, respectively.
Toxicities
Severe BM hypoplasia occurred in all patients with a mean hospitalization of 27 days (range 6-51). Hematological recovery was evaluated only in patients achieving CR: median time to reach neutrophils >1OOOIIlL and PLTs >20,0001IlL was 18 days (range 10-27) and 25 days (range 13-28), respectively. Mean duration ofG-CSF administration was 22 days (range [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Supportive treatment consisted ofa mean of9 packed red cell units (range 2-18) and 8 PLT units (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Table 11 reports the toxicity data. Fever developed in twenty-four of 35 patients (68.6%) during the period of neutropenia secondary to chemotherapy. There were 12 cases of fever of unknown origin (FUO) and 19 due to documented grade 2-3 infections (17 bacterial and 2 fungal). The mean number of days with febrile neutropenia was 5 (range 0-18). Antibiotics were administered for a mean of 9 days (range 0-28). Grade 1-2 nausea and oral mucositis were commonly observed (181 35, 51%) and only 3 patients developed grade 3-4 mucositis. One patient (2.8%) experienced late grade 5 gastrointestinal toxicity. Six patients (17%) experienced grade 3-5 cardiovascular toxicity, three with concomitant grade 3 lung infection. Two early deaths due to cardiac arrest and multi-organ failure were observed. Two patients died in CR due to cardiac arrest apparently unrelated to FLAG-MYOCETM induction chemotherapy, at +20 and +30 days after discharge. All of them had previous history of cardiac disease. One grade 4 ventricular arrhythmia following grade 3 hypokaliemia and one grade 3 atrial fibrillation were observed. 
DISCUSSION
In elderly patients with AML, the FLAG-Myocet" regimen seems to yield encouraging CR rates compared to prior regimens. In a previous study carried-out at our Institution on 41 younger patients, we showed a 56% CR in patients with AML receiving FLAG regimen (15) . Furthermore, remission duration after FLAG regimen alone remains short, suggesting that a more intensive induction with addition of anthracycline or post-remission therapy are required to achieve a higher survival rate in these patients. To this end, we investigated the approach of the FLAG plus MYOCET" (a non-pegylated liposomal formulation of doxorubicin) combination. Overall, a CR rate of 63% was achieved: in patients with newly-diagnosed and relapsed AML the CR rate were 68% and 75%, respectively versus 50% of secondary AML.
In this study with a maximum follow-up of 52 months (median 12 months) at one-year and 2-year, DFS were 78.9% and 26.7%, respectively. These results are clinically significant if we consider that 34% of the patients had secondary AML; these patients are generally known to be poorly responsive. Similar results were observed by Pastore (22) in a much younger population with refractory/ relapsed AML, treated with combination of FLAG plus idarubicin.
In this study, the FLAG-Myocet''' protocol enabled the administration of post-remission therapy in 45% of patients. This goal can be considered important as other studies from the literature report only a small percentage of elderly patients who can undergo additional therapies due to hematological toxicity or early relapse. In fact, one patient underwent allogeneic HSCT from an HLA-identical sibling and seven (20%) patients received ASCT after CD34+ cell mobilization. Eight patients in CR, considered not eligible for transplantation, received maintenance with GO, a recombinant humanized monoclonal antibody conjugated to the antitumor antibiotic calicheamicin targeting the CD33+ cell surface marker expressed on blast cells in the majority of AML patients. In a previous study (23), we showed a beneficial effect of GO as maintenance therapy after ASCT in 5 elderly AML patients. Our results differed from those of other studies (24) where post-remission treatment with GO in old AML patients not submitted to ASCT did not provide benefits regarding any clinical end-points. However, the number of patients are very small, precluding a meaningful analysis. Regarding toxicity, Myocet" has an acceptable cardiotoxicity profile in the population of this age (median age 69 years) which also had a large number of cardiovascular co-morbidities. Among six patients (17%) who experienced CTC grade 3-5 cardiovascular toxicity, two early deaths were observed. Two patients died in CR due to cardiac arrest apparently unrelated to previous chemotherapy. All these patients had previous history of cardiac disease.
We believe that the current study has some limitations. First, it was set up as a single-centre study: larger studies with a control group should be planned to confirm the results of the current study and to evaluate also the pharmaco-economic aspect in view of the relatively high cost of the compound. As already mentioned, we showed an encouraging CR rate compared with that reported in other studies. Furthermore, as reported by Latagliata (25) , who showed that liposomal daunorubicin seems to improve OS and DFS in long-term follow-up due to a reduction in late relapses, we also found that liposomal formulation of doxorubicin did result in longer DFS. This could be due to a prolonged effect of Myocet'", as well as of post-remission treatment (maintenance with GO and/or ASCT) or all of the above together. These issues also need further investigation.
Lastly, we could not collect cytogenetic or molecular biology data for all patients (unfavorable chromosomal abnormalities, presence of FLT3 mutation together with a low PS are a well-known negative prognostic factors in elderly patients,). However, the results look promising if we consider that one-third of the patients had secondary AML, which is known to be poorly responsive.
In conclusion, in elderly AML patients the new treatment protocol with Fl.Afi-Myocet" combination shows promising efficacy, allowing most patients to receive further treatments. Furthermore, the safety profile of this combination is quite good.
